Research analysts covering Kraig Biocraft Laboratories.
Recent press releases and 8-K filings for KBLB.
Kraig Biocraft Laboratories Prepares for First Commercial Spider Silk Deliveries
KBLB
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Kraig Biocraft Laboratories (KBLB) is preparing to deliver its first fiber samples to three previously announced companies in the fashion and performance textiles sectors, which are planned to be the company's first commercial sales.
- These deliveries mark the culmination of nearly two decades of innovation and scale-up, positioning KBLB to capture early-mover advantage in eco-luxury apparel.
- The planned shipments are significant as they represent the first commercial revenue-producing transactions in KBLB's history, implying that recombinant spider silk is ready for market-scale testing.
- KBLB's production system, utilizing genetically engineered silkworms, provides a scalable and cost-effective model for producing spider silk, unmatched by fermentation-based competitors.
Jan 14, 2026, 1:05 PM
Kraig Biocraft Laboratories Scales Up Spider Silk Production
KBLB
New Projects/Investments
Revenue Acceleration/Inflection
- Kraig Biocraft Laboratories (KBLB) is recognized as the leader in recombinant spider silk technology, a material with unique properties suitable for applications in defense, performance textiles, and medical fields.
- The company has overcome the challenge of scaling spider silk production through genetically engineered silkworms, enabling industrial-scale output.
- KBLB has acquired three strategic mulberry fields and is deploying over one million BAM-1 Alpha hybrid eggs to aggressively ramp up production, integrating critical feedstock into its rearing cycles.
- This operational expansion, supported by improved logistics and a Southeast Asian government partnership, is moving spider silk closer to sustained commercial output.
Jan 8, 2026, 2:32 PM
Kraig Biocraft Laboratories Pivots to Scalable Spider Silk Business
KBLB
New Projects/Investments
Product Launch
- Kraig Biocraft Laboratories (KBLB) is entering a defining phase in its corporate and scientific evolution, transitioning its spider silk technology from R&D validation to a viable and scalable business model.
- The company utilizes proprietary genetic engineering to produce recombinant spider silk at an industrial scale using transgenic silkworms, having developed advanced materials such as Monster Silk® and Dragon Silk™.
- By 2025, Kraig Labs established multiple production centers in Asia, expanding to dual-facility operations and achieving its largest production runs in company history.
- Kraig Labs is positioning its spider silk platform for commercialization in multi-billion-dollar market opportunities, including performance textiles, defense, luxury goods, and industrial composites.
Jan 6, 2026, 1:05 PM
Kraig Biocraft Laboratories Pivots to Scalable Spider Silk Production
KBLB
New Projects/Investments
Revenue Acceleration/Inflection
Product Launch
- Kraig Biocraft Laboratories (KBLB), a biotechnology company specializing in spider silk-based fiber technologies, is entering a defining phase of its corporate and scientific evolution, transitioning from a visionary concept to a viable business model.
- The company leverages proprietary genetic engineering to produce recombinant spider silk at an industrial scale using transgenic silkworms, having developed advanced materials like Dragon Silk™ and Monster Silk®.
- After extensive R&D, Kraig Labs has shifted focus to commercial scalability, establishing multiple production centers in Asia to ensure continuous fiber output and achieve its largest production runs in company history.
- KBLB is positioning its recombinant spider silk platform for applications in performance textiles, defense, luxury goods, and industrial composites, targeting potential multi-billion-dollar market opportunities.
Dec 10, 2025, 1:05 PM
Kraig Biocraft Laboratories Expands Spider Silk Production Capabilities
KBLB
New Projects/Investments
Hiring
Product Launch
- Kraig Biocraft Laboratories (KBLB) is expanding its infrastructure and workforce to scale up its spider silk production.
- The company secured rights to government-owned mulberry gardens near its Southeast Asian operations, which will support the scaling and logistical efficiency needed for its recombinant spider silk production.
- This expansion aims to meet commercial demand, including a recently announced order from a leading performance sports apparel brand, and to prepare for the expected commercialization of its BAM-1 Alpha hybrid spider silk.
Dec 8, 2025, 2:43 PM
Kraig Biocraft Laboratories Secures Spider Silk Order from Global Performance Sports Brand
KBLB
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Kraig Biocraft Laboratories (KBLB) is fulfilling an order for customized spider silk yarns from a globally recognized performance sports apparel brand as part of a confidential pilot development program.
- This order represents a significant commercialization step for Kraig Labs, marking the delivery of spider silk super fibers engineered for elite-tier athletic applications, with materials expected to ship before the end of the first quarter.
- The pilot program is the first commercial deployment of Kraig Labs’ next-gen fibers into a globally recognized athletic development pipeline, validating the company's scalable recombinant spider silk platform and its performance value.
- This milestone signals a transition from development to early commercialization for Kraig Labs, which has expanded its production footprint in Southeast Asia and is positioned as the first company to demonstrate repeatable, industrially scalable production of recombinant spider silk.
Nov 18, 2025, 12:05 PM
Kraig Biocraft Laboratories Nears Initial Spider Silk Deliveries and Deploys BAM-1 Alpha Platform
KBLB
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- Kraig Biocraft Laboratories (KBLB) is nearing initial deliveries of its recombinant spider silk, with the first large-scale deployment of its BAM-1 Alpha platform in its 2025 production program.
- The BAM-1 Alpha platform represents the most advanced evolution of Kraig Labs' biotech, designed to enable continuous, scalable output from genetically engineered silkworms.
- The company's ramp-up across its Southeast Asia-based rearing operations, including dual-facility expansion and recent production advancements, positions it to potentially ship commercial quantities of high-performance silk fibers sooner than expected.
- If production remains on track through the fourth quarter, Kraig Labs anticipates heading into 2026 with tangible proof of scalability, which could accelerate commercial relationships and revenue visibility.
Nov 17, 2025, 1:54 PM
Kraig Biocraft Laboratories Nears Commercial Spider Silk Delivery
KBLB
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Kraig Biocraft Laboratories (KBLB) is described as the global leader in spider silk development, on the verge of commercial delivery of high-performance recombinant spider silk.
- The company's breakthrough involves genetically engineering silkworms to produce spider silk (Dragon Silk™ and Monster Silk®), providing a scalable, natural, and cost-effective production method.
- Kraig Labs is preparing to deliver its first fiber and fabric samples to three previously announced customers, which are expected to represent its initial commercial sales.
- This development positions KBLB to achieve what other companies and national projects, despite investing hundreds of millions, have not: commercially viable spider silk production.
Nov 10, 2025, 1:35 PM
Kraig Biocraft Laboratories announces commercial deliveries of recombinant spider silk
KBLB
Product Launch
- Kraig Biocraft Laboratories (KBLB) is preparing for the first commercial deliveries of recombinant spider silk fibers and fabrics to three previously announced customers in the fashion and performance textile sectors.
- In 2025, KBLB achieved record-breaking yields at its Asia-based rearing and manufacturing facilities, positioning the company as the first true commercial producer of recombinant spider silk.
- The company's proprietary silkworm-based genetic engineering platform produces spider silk that is up to five times stronger than steel by weight and tougher than Kevlar, while also being biodegradable and renewable.
- KBLB's technology targets the global textile and advanced materials markets, which are estimated to exceed $1 trillion, spanning sectors like fashion, aerospace, biomedical engineering, and defense.
Nov 4, 2025, 1:35 PM
Kraig Biocraft Laboratories Positions for Multi-Billion-Dollar Eco-Luxury Apparel Market
KBLB
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- Kraig Biocraft Laboratories (KBLB) is positioning itself at the forefront of a potential multi-billion-dollar eco-luxury apparel market through the development and commercialization of spider silk.
- The company's proprietary transgenic silkworm technology has enabled synthetic spider silk production to reach meaningful commercial scale, making sustainable spider silk garments producible at scale and competitive price points.
- Market analyses suggest the synthetic spider silk apparel market could reach $1.4 to $2.1 billion annually by 2030, potentially expanding to $3+ billion by 2035.
- KBLB leverages existing silkworm farming infrastructure, providing a clear path to both scale and pricing competitiveness for its spider silk materials.
Oct 29, 2025, 12:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more